FDA Tells K-V: Enforcement Discretion Unchanged By New Compounding Authorities

Drug Industry Daily
The FDA does not intend to prevent compounders from making preterm birth drug Makena (hydroxyprogesterone caproate), the agency stated in a legal filing last week that outlines how it intends to approach one contentious issue involving compounders.

To View This Article:


Subscribe To Drug Industry Daily